Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

about

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

Item

http://www.wikidata.org/entity/Q57191804

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 20 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

@en

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

@nl

type

Item

label

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

@en

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

@nl

prefLabel

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

@en

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

@nl

P1476

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

@en

P2093

Alexandra Savova

http://www.w3.org/2001/XMLSchema#string

Daniela Grekova

http://www.w3.org/2001/XMLSchema#string

Manoela Manova

http://www.w3.org/2001/XMLSchema#string

Maria Vasileva

http://www.w3.org/2001/XMLSchema#string

Silvia Terezova

http://www.w3.org/2001/XMLSchema#string

P2860

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

The changing landscape of biosimilars in rheumatology

The economics of biosimilars.

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries

Economic burden of rheumatoid arthritis: a systematic review.

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries.

P304

1070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2018.01070

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Valentina Petkova

G Petrova

Maria Kamusheva

P577

2018-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30294275

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

P932

6158404

http://www.w3.org/2001/XMLSchema#string